Coherus Oncology, Inc. (CHRS) Stock

Coherus Oncology, Inc. (CHRS) is a Healthcare stock trading at $1.47 (as of 2026-06-18), with a market capitalization of $245.26M and a trailing P/E of 0.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Coherus Oncology, Inc. is a biopharmaceutical company that researches, develops, and commercializes therapies for cancer and other conditions. Its portfolio includes immunotherapies such as the UDENYCA biosimilar and investigational antibodies and agents including LOQTORZI and multiple candidates targeting immune or tumor-related pathways.

Valuation — source: SEC EDGAR (first-party)
Price$1.47
Market Cap$245.26M
P/E Ratio0.8
EV / EBITDA-0.6
Price / Book2.71
Price / Sales4.54
DCF Value (model)$-15.14
DCF Upside vs Price-1129.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$42.17M
Net Margin398.4%
Return on Equity236.9%
Current Ratio1.56
Revenue Growth (YoY)-84.2%
EPS Growth (YoY)472.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-8.67 (distress)
Valuation vs Sector & Industry
Stock P/E0.8
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-96.0%
vs Industry-95.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($43.91M)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODennis Lanfear
Employees228
CountryUS
IPO Date2014-11-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • C4 Therapeutics, Inc. (CCCC)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • SAB Biotherapeutics, Inc. (SABS)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Minerva Neurosciences, Inc. (NERV)
  • Alector, Inc. (ALEC)
  • Genelux Corporation (GNLX)
  • LifeVantage Corporation (LFVN)
CHRS earnings history · CHRS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.